Get the Stockscreener App
53.32
6.36%
-3.62
After Hours:
53.32
Tarsus Pharmaceuticals Inc stock is traded at $53.32, with a volume of 580.40K.
It is down -6.36% in the last 24 hours and down -5.12% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$56.94
Open:
$56.57
24h Volume:
580.40K
Relative Volume:
0.93
Market Cap:
$2.04B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-11.49
EPS:
-4.64
Net Cash Flow:
$-123.00M
1W Performance:
+3.05%
1M Performance:
-5.12%
6M Performance:
+130.42%
1Y Performance:
+80.14%
1-Day Range:
$52.57
$56.96
1-Week Range:
$51.84
$57.28
52-Week Range:
$20.08
$57.28
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
53.32 | 2.04B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 12-Month HighShould You Buy? - MarketBeat
Jennison Associates LLC Has $138.43 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Janney Montgomery Scott LLC Sells 2,218 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by E. Ohman J or Asset Management AB - MarketBeat
Strong Growth Prospects and Market Expansion Drive Buy Rating for Tarsus Pharmaceuticals - TipRanks
Breakeven On The Horizon For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Yahoo Finance
BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74 -February 03, 2025 at 10:36 am EST - Marketscreener.com
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire
Exclusive Access: Tarsus Pharma's Double-Header at Elite Healthcare Investment Forums - StockTitan
How To Trade (TARS) - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $62.00 Price Target at Barclays - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 9% After Analyst Upgrade - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 9% Higher After Analyst Upgrade - MarketBeat
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts - Benzinga
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $62.00 at Barclays - MarketBeat
Oppenheimer lifts Tarsus stock target, impressed by execution and ocular rosacea potential - MSN
Tarsus Pharmaceuticals Inc (NASDAQ: TARS): An Enticing Stock To Watch - Stocks Register
Midday Stock Roundup: Virgin Galactic down 2.3% and 87% YoY - Orange County Business Journal
Tarsus: Promising Investment, But Timing Is The Key (NASDAQ:TARS) - Seeking Alpha
Oppenheimer Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $72.00 - MarketBeat
First Week of TARS March 21st Options Trading - Nasdaq
Tarsus PharmaceuticalEye Care Therapeutics - MSN
Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals reshuffles board, appoints new committee chair - MSN
Grant GrossMendelsohn LLC Sells 14,331 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $54.20 Average Target Price from Analysts - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tarsus Pharmaceuticals (NASDAQ:TARS) Publishes Corporate Presentation – Enhances Stakeholder InsightOn January 13, 2025, Tarsus Pharmaceuticals, Inc. shared its corporate presentation on its website’s Investor & News section, as detailed in the lates - Defense World
Tarsus Pharmaceuticals, Inc Announces Board and Committee Changes -January 17, 2025 at 05:09 pm EST - Marketscreener.com
Assenagon Asset Management S.A. Buys 5,565 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround - MSN
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 6.3%Time to Sell? - MarketBeat
Tarsus Pharmaceuticals is Now Oversold (TARS) - Nasdaq
Tarsus CEO Bobby Azamian: Clearing Crusty Eyelids with Xdemvy - Orange County Business Journal
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap DownTime to Sell? - MarketBeat
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY - WICZ
Tarsus Provides 2025 Update: Accelerating the Launch of - GlobeNewswire
Tarsus' XDEMVY Eye Treatment Hits $113M Sales, Plans New Rosacea Drug Development - StockTitan
Analysts Expect Breakeven For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Before Long - Simply Wall St
JPMorgan Chase & Co. Has $14.48 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
JPMorgan Chase & Co. Buys 420,057 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength? - Yahoo Finance
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):